Drug General Information (ID: DDI5XHJDRI)
Drug Name			Levacetylmethadol		Drug Info		Tolevamer		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Potassium-Binding Resin
Structure

Mechanism of Levacetylmethadol-Tolevamer Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Levacetylmethadol				Tolevamer
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Levacetylmethadol and Tolevamer

Recommended Action
Management		Caution is advised if levomethadyl acetate must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with levomethadyl acetate. A 12-lead ECG should be performed before initiating therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to immediately seek medical attention if they experience palpitations, dizziness, lightheadedness, fainting, or seizures.

References
1	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
2	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
3	Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON.